Summary of BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRC

00:00:00 - 00:00:00

The Breakwater study is an international Phase 3 study that is looking at the standard of care chemotherapy (pulpox and venice) in combination with various chemotherapy backbones in addition to ankle refined advanced pancreatic cancer therapy. The study is powered to look at the PFS with key secondary endpoints of overall survival. The study is enrolling in multiple studies in multiple countries and has just completed a safety lead. This will be used to guide the dosing in the Phase 3 study.

• 00:00:00 The Breakwater study is an international Phase 3 study looking at standard of care chemotherapy (pulpox and venice) in combination with various chemotherapy backbones in addition to ankle refined advanced pancreatic cancer therapy. The study is powered to look at PFS with key secondary endpoints of overall survival. The study is enrolling in multiple studies in multiple countries and has just completed a safety lead. This will be used to guide the dosing in the Phase 3 study.